Shares of Zafgen, Inc. (NASDAQ:ZFGN) have been assigned a consensus recommendation of “Hold” from the seven ratings firms that are covering the stock. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $16.75.
Separately, Zacks Investment Research upgraded shares of Zafgen from a “hold” rating to a “buy” rating and set a $4.50 price target on the stock in a research note on Thursday, January 12th.
In related news, Director Frances K. Heller acquired 10,000 shares of the stock in a transaction dated Monday, December 19th. The stock was acquired at an average cost of $3.23 per share, with a total value of $32,300.00. Following the completion of the transaction, the director now owns 30,000 shares in the company, valued at approximately $96,900. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 20.30% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the stock. State Street Corp increased its position in shares of Zafgen by 4.2% in the fourth quarter. State Street Corp now owns 352,963 shares of the biopharmaceutical company’s stock worth $1,122,000 after buying an additional 14,353 shares during the period. Spark Investment Management LLC increased its position in shares of Zafgen by 73.5% in the third quarter. Spark Investment Management LLC now owns 347,500 shares of the biopharmaceutical company’s stock worth $1,150,000 after buying an additional 147,200 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Zafgen by 41.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 306,462 shares of the biopharmaceutical company’s stock worth $975,000 after buying an additional 89,805 shares during the period. Federated Investors Inc. PA increased its position in shares of Zafgen by 27.0% in the fourth quarter. Federated Investors Inc. PA now owns 129,661 shares of the biopharmaceutical company’s stock worth $412,000 after buying an additional 27,533 shares during the period. Finally, Schwab Charles Investment Management Inc. increased its position in shares of Zafgen by 196.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 70,172 shares of the biopharmaceutical company’s stock worth $421,000 after buying an additional 46,500 shares during the period. 50.64% of the stock is owned by hedge funds and other institutional investors.
“Zafgen, Inc. (ZFGN) Receives Consensus Rating of “Hold” from Analysts” was first published by sleekmoney and is owned by of sleekmoney. If you are viewing this news story on another publication, it was illegally copied and republished in violation of US & international copyright and trademark legislation. The correct version of this news story can be read at http://sleekmoney.com/zafgen-inc-zfgn-receives-consensus-rating-of-hold-from-analysts/1659624.html.
Shares of Zafgen (NASDAQ:ZFGN) opened at 4.18 on Tuesday. The stock has a 50 day moving average of $3.90 and a 200 day moving average of $3.43. The stock’s market cap is $114.25 million. Zafgen has a 52 week low of $2.89 and a 52 week high of $8.56.
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/zafgen-inc-zfgn-receives-consensus-rating-of-hold-from-analysts/1659624.html
Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.